BridgeBio Pharma, Inc.

Public biopharmaceutical company fundraising activity in late June and early July was somewhat remarkable after the BIO International Convention in early June, during which drug developers and investo

Bayer’s pharmaceuticals unit enjoyed a surprisingly strong quarter at the start of 2025 but CEO Bill Anderson has said he would not be upping full-year forecasts for the division, given the “present g

BridgeBio Pharma’s Attruby (acoramidis) delivered $36.7m in sales during the first quarter of 2025 – three times analyst consensus of $12m for the transthyretin amyloidosis with cardiomyopathy (ATTR-C

Alnylam Pharmaceuticals’ Amvuttra (vitrisiran) will tap a substantially larger commercial opportunity with its US Food and Drug Administration approval for the treatment of ATTR with cardiomyopathy, b